Electromed, Inc. (ELMD)

In August 2025, Electromed reported record Q4 and annual revenue, completed a share repurchase, and was added to the Russell indexes. In November 2025, the company announced Q1 FY2026 financial results with increased net revenues and income, held its shareholders meeting, and saw its composite rating climb. In December 2025, Electromed entered a new credit facility, presented at an equity conference, and maintained a high composite rating. In January 2026, Electromed's shares increased, and the company joined the rank of stocks with a 95-plus composite rating. In February 2026, Electromed is scheduled to report its Q2 Fiscal 2026 financial results.

Data on Electromed, Inc.'s demand seasonality exists, with platforms displaying mean and median monthly returns to identify seasonal patterns. However, the specific details of these seasonal patterns for Electromed’s products and services are not explicitly provided in the available snippets.

Electromed, Inc. is a medical device company focused on developing, manufacturing, marketing, and selling airway clearance therapy products. Operating in the Medical Devices industry, specifically the Electromedical & Electrotherapeutic Apparatus sector, Electromed designs, produces, and distributes High Frequency Chest Wall Oscillation (HFCWO) airway clearance products, primarily for home use. Key products include the SmartVest Airway Clearance System, SmartVest SQL System, and SmartVest Clearway System, along with SmartVest Connect for data tracking and single-patient use SmartVest products for acute care. These products support individuals with compromised pulmonary function, including those with bronchiectasis, cystic fibrosis, and neuromuscular conditions.

Electromed, Inc. operates manufacturing and distribution facilities within the United States and serves a growing international customer base. While primarily focused on the U.S. market, international sales accounted for approximately 1% of net revenues in both fiscal years 2023 and 2022. The company sells its products outside the U.S. through independent distributors specializing in respiratory products, located in Europe, the Arab states of the Persian Gulf, Southeast Asia, South America, and Central America. The company's headquarters are in New Prague, Minnesota.

Electromed, Inc. has maintained a generally positive brand reputation, reflected in analyst ratings and market sentiment. The company has received a consensus rating of "Buy" from analysts, supported by substantial growth in homecare revenue, increased distributor and hospital sales, and strategic investments. However, concerns have been raised about potential challenges, including margin compression, increasing competitive pressures, and diminished sales representative productivity. The stock's decline from a peak of $35.43 to approximately $18 has also been noted as reflecting investor concerns.

Electromed, Inc. has significant institutional ownership, with 194 institutional owners and shareholders holding 4,680,815 shares, representing 53.31% of the company's shares. Major institutional shareholders include Vanguard Group Inc and BlackRock, Inc. Insider ownership stands at 21.3%. Over the last year, insider sentiment has been negative due to significant open-market selling from key executives, with insiders selling $20.2 million worth of stock.